» Articles » PMID: 33672735

Cellular Mechanism Underlying Highly-Active or Antiretroviral Therapy-Induced Lipodystrophy: Atazanavir, a Protease Inhibitor, Compromises Adipogenic Conversion of Adipose-Derived Stem/Progenitor Cells Through Accelerating ER Stress-Mediated Cell...

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Mar 6
PMID 33672735
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Lipodystrophy is a common complication in human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) or antiretroviral therapy (ART). Previous studies demonstrated that endoplasmic reticulum (ER) stress-mediated unfolded protein response (UPR) is involved in lipodystrophy; however, the detailed mechanism has not been fully described in human adipogenic cell lineage. We utilized adipose tissue-derived stem cells (ADSCs) obtained from human subcutaneous adipose tissue, and atazanavir (ATV), a protease inhibitor (PI), was administered to ADSCs and ADSCs undergoing adipogenic conversion. Marked repression of adipogenic differentiation was observed when ATV was administered during 10 days of ADSC culture in adipogenic differentiation medium. Although ATV had no effect on ADSCs, it significantly induced apoptosis in differentiating adipocytes. ATV treatment also caused the punctate appearance of CCAAT-enhancer-binding (C/EBP) protein homologous protein (CHOP), and altered expression of CHOP and GRP78/Bip, which are the representation of ER stress, only in differentiating adipocytes. Administration of UPR inhibitors restored adipogenic differentiation, indicating that ER stress-mediated UPR was induced in differentiating adipocytes in the presence of ATV. We also observed autophagy, which was potentiated in differentiating adipocytes by ATV treatment. Thus, adipogenic cell atrophy leads to ATV-induced lipodystrophy, which is mediated by ER stress-mediated UPR and accelerated autophagy, both of which would cause adipogenic apoptosis. As our study demonstrated for the first time that ADSCs are unsusceptible to ATV and its deleterious effects are limited to the differentiating adipocytes, responsible target(s) for ATV-induced lipodystrophy may be protease(s) processing adipogenesis-specific protein(s).

Citing Articles

Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas.

Papantoniou E, Arvanitakis K, Markakis K, Papadakos S, Tsachouridou O, Popovic D Life (Basel). 2024; 14(4).

PMID: 38672720 PMC: 11051320. DOI: 10.3390/life14040449.


PPARγ Gene as a Possible Link between Acquired and Congenital Lipodystrophy and its Modulation by Dietary Fatty Acids.

Rodriguez-Garcia C, Sanchez-Quesada C, Martinez-Ramirez M, Gaforio J Nutrients. 2022; 14(22).

PMID: 36432429 PMC: 9693235. DOI: 10.3390/nu14224742.


Linear and non-linear analysis of heart rate variability in HIV-positive patients on two different antiretroviral therapy regimens.

Goncalves A, Braga M, Santana P, Resende L, da Silva V, Correia D BMC Infect Dis. 2021; 21(1):1022.

PMID: 34587909 PMC: 8482565. DOI: 10.1186/s12879-021-06648-w.


Fibrosis, the Bad Actor in Cardiorenal Syndromes: Mechanisms Involved.

Delgado-Valero B, Cachofeiro V, Martinez-Martinez E Cells. 2021; 10(7).

PMID: 34359993 PMC: 8307805. DOI: 10.3390/cells10071824.

References
1.
de Waal R, Cohen K, Maartens G . Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One. 2013; 8(5):e63623. PMC: 3665842. DOI: 10.1371/journal.pone.0063623. View

2.
Bresciani E, Saletti C, Squillace N, Rizzi L, Molteni L, Meanti R . miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir. Front Pharmacol. 2019; 10:461. PMC: 6524698. DOI: 10.3389/fphar.2019.00461. View

3.
Bunnell B, Flaat M, Gagliardi C, Patel B, Ripoll C . Adipose-derived stem cells: isolation, expansion and differentiation. Methods. 2008; 45(2):115-20. PMC: 3668445. DOI: 10.1016/j.ymeth.2008.03.006. View

4.
Kim R, Wilson C, Wabitsch M, Lazar M, Steppan C . HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring). 2006; 14(6):994-1002. DOI: 10.1038/oby.2006.114. View

5.
Mallewa J, Wilkins E, Vilar J, Mallewa M, Doran D, Back D . HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother. 2008; 62(4):648-60. DOI: 10.1093/jac/dkn251. View